$IVST Morningstar analysts note that the biotech i
Post# of 7843

The analysts note that a perfect storm of bearish activity began to overtake biotech in early 2015, which has led to a period of underperformance. Exacerbated valuations, ending drug cycles, and a tumultuous U.S. presidential election helped push biotech stocks down the past couple of years.
https://finance.yahoo.com/news/innovest-globa...00841.html

